26 related articles for article (PubMed ID: 20805755)
1. Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006).
Arbyn M; Fabri V; Temmerman M; Simoens C
PLoS One; 2014; 9(4):e92615. PubMed ID: 24690620
[TBL] [Abstract][Full Text] [Related]
2. Cytological pattern of cervical Papanicolaou smear in eastern region of Saudi Arabia.
Balaha MH; Al Moghannum MS; Al Ghowinem N; Al Omran S
J Cytol; 2011 Oct; 28(4):173-7. PubMed ID: 22090690
[TBL] [Abstract][Full Text] [Related]
3. Cervix cancer screening in Croatia within the European Cervical Cancer Prevention Week.
Skopljanac-Macina L; Mahovlić V; Ovanin-Rakić A; Barisić A; Rajhvajn S; Juric D; Babić D; Corusić A; Oresković S
Coll Antropol; 2010 Jun; 34(2):613-7. PubMed ID: 20698138
[TBL] [Abstract][Full Text] [Related]
4. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.
Nygård M; Daltveit AK; Thoresen SO; Nygård JF
BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
6. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
7. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
8. Cytological screening for cervical cancer in the province of Limburg, Belgium.
Arbyn M; Van Nieuwenhuyse A; Bogers J; De Jonge E; De Beeck LO; Matheï C; Buntinx F
Eur J Cancer Prev; 2011 Jan; 20(1):18-24. PubMed ID: 20805755
[TBL] [Abstract][Full Text] [Related]
9. [Cancer of the cervix uteri: analysis of the cost-benefit and efficacy of opportunistic screening versus organized screening].
Castronovo V; Foidart JM; Boniver J
Rev Med Liege; 1998 May; 53(5):305-7. PubMed ID: 9689888
[TBL] [Abstract][Full Text] [Related]
10. Belgian consensus guidelines for follow-up of women with cervical cytological abnormalities.
Cuvelier CA; Bogers JP; Bourgain C; Delvenne P; Drijkoningen M; Garbar C; Kevers M; Remmelinck M; Thienpont L; Verhest A; Weynand B; Willocx F
Acta Clin Belg; 2009; 64(2):136-43. PubMed ID: 19432026
[TBL] [Abstract][Full Text] [Related]
11. ABC3 Part II: a review of the new criteria for evaluating cervical cytology in England.
Blanks RG
Cytopathology; 2012 Dec; 23(6):360-70. PubMed ID: 23173805
[TBL] [Abstract][Full Text] [Related]
12. [French pathologist' implication in cervical cancer screening].
Vacher-Lavenu MC
Ann Pathol; 2006 Oct; 26(5):369-74. PubMed ID: 17255925
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
